COMPASS Cancer Research
Combining healthcare economics with clinical analysis, this report outlines the strategy for affordable cancer care. From early diagnosis to late stage disease, cancer care too often involves unnecessary or inappropriate intervention, increasing cost and clinical burden; driving momentum for precision medicine. Rapid developments in biomarkers and increasingly accurate diagnosis will facilitate early intervention through robot- enabled minimally invasive surgery and locally delivered radiotherapy. Combinations of new immunotherapies with targeted drugs will provide patients with improved longer lasting outcomes. Greater precision will also extend to drug development as technology improves target selection and drug design and markers facilitate clinical trial design. We highlight some innovative companies at the vanguard of this developing strategy; already out-performing their non-cancer market peers.